SQ Innovation will use Ligand’s Captisol technology to achieve a smaller delivery volume for more cost-effective diuretic treatment in heart failure.
This novel furosemide combination product is currently under investigation and is not approved by the FDA.
SQ Innovation will use Ligand’s Captisol technology to achieve a smaller delivery volume for more cost-effective diuretic treatment in heart failure.
Sign up for our email list below to receive periodic updates from SQ Innovation, Inc. on the Lasix SQF Infusion as we continue development and go to market.